Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing, dated November 1, 2024, reports on a transaction by a Person Discharging Managerial Responsibilities (PDMR) in accordance with the UK Market Abuse Regulation. The filing concerns Dawn Allen, the incoming Chief Financial Officer (CFO) effective November 1, 2024. Haleon Plc is a global leader in consumer health with brands including Advil, Sensodyne, and Panadol.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation awards.
Material Changes and Transactions
The primary material event is the grant of share awards to Dawn Allen on October 31, 2024, to compensate for forfeited incentive payments from her previous employment. The total aggregated volume of shares awarded is 1,250,303 ordinary shares. The price per share for these grants is listed as Nil. The awards include:
- Performance Share Plan (Buyout) awards vesting in June 2025, June 2026, and June 2027.
- Share Value Plan (Buyout) awards vesting in November 2024 and June 2025.
- A pro-rated Performance Share Plan (Interim) award vesting in March 2027.
All awards are subject to continued employment, performance conditions, malus, and clawback provisions.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business performance. The primary risk disclosed relates to the vesting conditions of the awards, which depend on continued employment and the achievement of performance targets (disclosed in the 2023 Annual Report). There are no unusual items or contingencies reported in this specific filing.
Key Facts for Investor Verification
- Verify the specific performance targets attached to the Performance Share Plan awards in the 2023 Annual Report and Form 20-F.
- Confirm the total number of shares granted (1,250,303) and the vesting schedule for the incoming CFO.
- Note that these awards are "buyout" grants intended to replace forfeited compensation from a prior employer.
- Understand that the filing does not contain operational or financial results for the period.